David Mountcastle Sells 5,361 Shares of Privia Health Group (NASDAQ:PRVA) Stock

March 3, 2026 by InsiderTrades.com

Key Points

Director sale: Director Matthew Shawn Morris sold 16,550 shares on Feb. 27 at an average of $25 (part of ~24,338 shares sold Feb. 26–27 totaling ~$608k), trimming his position to 68,188 shares — a move that may raise short‑term selling‑pressure or sentiment questions.
Strong quarterly results and catalysts: Privia beat estimates with $0.25 EPS vs $0.04 expected and revenue of $541.2M (+17.4% YoY), is acquiring Evolent’s ACO business to expand value‑based care, and analysts have lifted price targets (consensus ≈ $30.93).
Additional insider selling: CFO David Mountcastle also sold ~13,058 shares (~$327k) across Feb. 26–27 while continuing to hold 172,909 shares, a signal some investors watch closely alongside positive company news.

Privia Health Group, Inc. (NASDAQ:PRVA - Get Free Report) CFO David Mountcastle sold 5,361 shares of the stock in a transaction dated Thursday, February 26th. The stock was sold at an average price of $25.00, for a total transaction of $134,025.00. Following the sale, the chief financial officer directly owned 172,909 shares in the company, valued at approximately $4,322,725. This represents a 3.01% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.

David Mountcastle also recently made the following trade(s):

On Friday, February 27th, David Mountcastle sold 7,697 shares of Privia Health Group stock. The stock was sold at an average price of $25.05, for a total transaction of $192,809.85.
On Friday, December 12th, David Mountcastle sold 23,887 shares of Privia Health Group stock. The stock was sold at an average price of $25.03, for a total transaction of $597,891.61.

Privia Health Group Price Performance

PRVA opened at $24.04 on Tuesday. The stock has a market capitalization of $2.96 billion, a P/E ratio of 141.41, a price-to-earnings-growth ratio of 1.59 and a beta of 0.83. The company's 50 day simple moving average is $23.07 and its 200-day simple moving average is $23.52. Privia Health Group, Inc. has a one year low of $18.77 and a one year high of $26.51.

Privia Health Group (NASDAQ:PRVA - Get Free Report) last posted its quarterly earnings data on Thursday, February 26th. The company reported $0.25 earnings per share for the quarter, topping the consensus estimate of $0.04 by $0.21. The firm had revenue of $541.17 million during the quarter, compared to analysts' expectations of $516.61 million. Privia Health Group had a net margin of 1.08% and a return on equity of 3.06%. Privia Health Group's revenue was up 17.4% on a year-over-year basis. During the same quarter in the previous year, the company posted $0.21 EPS. As a group, analysts anticipate that Privia Health Group, Inc. will post 0.14 EPS for the current year.

Analyst Ratings Changes

PRVA has been the topic of several analyst reports. Barclays increased their price objective on shares of Privia Health Group from $22.00 to $23.00 and gave the company an "equal weight" rating in a report on Monday, November 10th. BMO Capital Markets assumed coverage on shares of Privia Health Group in a research note on Thursday, November 13th. They issued an "outperform" rating and a $30.00 target price for the company. Weiss Ratings reiterated a "hold (c)" rating on shares of Privia Health Group in a report on Monday, December 29th. Royal Bank Of Canada initiated coverage on shares of Privia Health Group in a report on Friday, January 9th. They issued an "outperform" rating and a $31.00 price target for the company. Finally, Jefferies Financial Group reiterated a "buy" rating and set a $32.00 target price on shares of Privia Health Group in a report on Thursday. Thirteen analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company's stock. According to MarketBeat.com, Privia Health Group presently has an average rating of "Moderate Buy" and a consensus price target of $30.93.

View Our Latest Analysis on PRVA

Privia Health Group News Summary

Here are the key news stories impacting Privia Health Group this week:

Positive Sentiment: Truist raised its price target on PRVA from $31 to $33 and reiterated a "buy" rating — the new target implies roughly ~37% upside from the current price, which can attract buyers and support the rally. Article Title
Positive Sentiment: Privia announced it will acquire Evolent’s ACO business to expand its value‑based care scale — a strategic deal that could boost managed-care revenue, accelerate margin improvement in value-based contracts, and justify higher multiples if integration succeeds. Privia Health Expands Value Based Care Scale With Evolent ACO Acquisition
Negative Sentiment: Director Matthew Shawn Morris sold a combined ~24,338 shares across Feb. 26–27 for about $608k; he still holds 68,188 shares. Significant director sales can create short‑term selling pressure or raise governance/sentiment questions for some investors. SEC filing: SEC Form 4
Negative Sentiment: CFO David Mountcastle sold a combined ~13,058 shares across Feb. 26–27 for roughly $327k; he continues to own 172,909 shares. Insider sales by senior finance executives are often watched closely and can temper enthusiasm from positive catalysts. SEC filing: SEC Form 4

Institutional Investors Weigh In On Privia Health Group

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Van Berkom & Associates Inc. raised its stake in shares of Privia Health Group by 30.1% in the 3rd quarter. Van Berkom & Associates Inc. now owns 3,774,565 shares of the company's stock valued at $93,987,000 after purchasing an additional 873,344 shares during the period. Vanguard Group Inc. boosted its position in shares of Privia Health Group by 5.3% during the third quarter. Vanguard Group Inc. now owns 12,098,933 shares of the company's stock worth $301,263,000 after buying an additional 607,447 shares during the period. ArrowMark Colorado Holdings LLC grew its holdings in shares of Privia Health Group by 139.4% during the fourth quarter. ArrowMark Colorado Holdings LLC now owns 841,266 shares of the company's stock worth $19,946,000 after buying an additional 489,866 shares in the last quarter. Algert Global LLC raised its position in Privia Health Group by 277.4% in the 3rd quarter. Algert Global LLC now owns 484,304 shares of the company's stock valued at $12,059,000 after buying an additional 355,966 shares during the last quarter. Finally, Freestone Grove Partners LP lifted its stake in Privia Health Group by 40.6% in the 4th quarter. Freestone Grove Partners LP now owns 1,213,342 shares of the company's stock valued at $28,768,000 after acquiring an additional 350,194 shares in the last quarter. 94.48% of the stock is currently owned by institutional investors and hedge funds.

About Privia Health Group

(Get Free Report)

Privia Health Group (NASDAQ: PRVA) is a physician enablement company that partners with independent physicians, medical groups and health systems to transform the delivery of patient care. Through a clinically integrated network and a proprietary technology platform, the company supports providers in managing population health, delivering coordinated care and optimizing financial performance under both fee-for-service and value-based reimbursement models.

Founded in 2016 and headquartered in McLean, Virginia, Privia Health has rapidly expanded its footprint to serve multiple metropolitan markets across the United States.